| PubMed |
Abstract |
RScore(About this table) |
| 17804677 |
Tavridou A, Kaklamanis L, Papalois A, Kourounakis AP, Rekka EA, Kourounakis PN, Charalambous A, Manolopoulos VG: EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit. J Pharmacol Exp Ther. 2007 Dec;323(3):794-804. Epub 2007 Sep 5.
EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide] inhibits squalene synthase and lipid biosynthesis and possesses antioxidant properties. |
112(1,2,2,2) |
Details |
| 19754389 |
Tavridou A, Manolopoulos VG: EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors. Curr Pharm Des. 2009;15(27):3167-78.
|
3(0,0,0,3) |
Details |
| 17922341 |
Tavridou A, Megaritis G, Kourounakis AP, Charalambous A, Manolopoulos VG: EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate endothelial nitric oxide synthase expression in cultured endothelial cells. Endothelium. 2007 Jul-Oct;14(4-5):239-43.
|
2(0,0,0,2) |
Details |
| 18520953 |
Tavridou A, Kaklamanis L, Papalois A, Kourounakis AP, Rekka EA, Kourounakis PN, Charalambous A, Manolopoulos VG: Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol-fed rabbit. J Cardiovasc Pharmacol. 2008 Jun;51(6):573-80.
|
2(0,0,0,2) |
Details |
| 18754614 |
Kourounakis AP, Charitos C, Rekka EA, Kourounakis PN: Lipid-lowering (hetero) aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5.
Most of the novel compounds are more active than the structurally related and reference biphenyl-morpholine, pointing to useful structural approaches for the design of antiatherosclerotic agents. |
2(0,0,0,2) |
Details |